Pfizer
Search results
Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll...
We promote health equity and seek to improve the health outcomes of populations disproportionately affected by serious diseases. Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
Bristol Myers Squibb focuses on developing new medicines to address the unmet medical needs of patients with serious diseases. Explore comprehensive information about our products including dosage and safety information.
Discover what it means to have a meaningful career. At Bristol Myers Squibb, you'll transform patients' lives and help them prevail over serious diseases.
Jun 24, 2022 · Bristol Myers Squibb: Creating a Better Future for People with Cancer Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.
Stay updated on the latest news from Bristol Myers Squibb, a global biopharmaceutical company dedicated to developing and delivering innovative medicines for serious diseases.
Studies highlight the range of targets and molecular approaches within the BMS multiple myeloma portfolio including bispecific T cell engager alnuctamab, first-in-class anti-BCMA CAR T cell therapy Abecma, GPRC5D CAR T (BMS-986393/CC-95266) and novel oral CELMoDTM agents mezigdomide and iberdomide.
